---
layout: default
title: Ganirelix
parent: 僅模型預測 (L5)
nav_order: 158
evidence_level: L5
indication_count: 10
---

# Ganirelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ganirelix: From Unlicensed GnRH Antagonist to Hypertrichosis (Low-Confidence Prediction)

## One-Sentence Summary

> Ganirelix's original indication is not on file — the drug is currently **not marketed in Taiwan** and no approved-indication text exists in this evidence pack; based on the repurposing rationale notes it is understood as a GnRH receptor antagonist. TxGNN's top-ranked prediction is **Hypertrichosis (disease)**, but this prediction is supported by **0 clinical trials and 0 publications**, and the evidence pack's own mechanistic review flags it as unsubstantiated.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — drug is unlicensed/not marketed in Taiwan, no indication text on file |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% (rank #420 among all predictions) |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for ganirelix is not available from DrugBank (data gap DG002). Based on the mechanistic annotations embedded in this evidence pack's repurposing rationale, ganirelix is a **GnRH receptor antagonist** — it blocks pituitary GnRH receptors and suppresses LH/FSH release, consistent with its known clinical role in reproductive endocrinology. No official original-indication text or license record exists because the drug is not currently marketed in Taiwan.

For the **top-ranked prediction (Hypertrichosis)**, the evidence pack's own mechanistic review is explicitly skeptical: hypertrichosis is etiologically heterogeneous (drug-induced, endocrine, genetic), and there is **no clear pathway connecting GnRH/gonadal-axis suppression to generalized hair overgrowth**, except possibly in androgen-driven subtypes — a link the rationale itself describes as "insufficient to support the hypothesis." This is reflected in the **L5 evidence level and Hold recommendation** assigned to this candidate.

Notably, several **lower-ranked candidates in this same prediction set show far stronger mechanistic coherence** than the top hit, because they involve conditions where the hypothalamic-pituitary-gonadal axis is the direct disease driver:
- **Central precocious puberty (rank 9)** — GnRH-driven premature LH/FSH pulsatility is the most direct pharmacological match for a GnRH antagonist.
- **Aromatase excess syndrome (rank 8)** — peripheral estrogen excess can secondarily trigger central precocious puberty, where GnRH antagonism could theoretically slow progression.
- **Familial male-limited precocious puberty (rank 6)** — mechanism is peripheral (LHCGR mutation), so relevance is directionally uncertain but flagged as a "Research Question."

These three are staged as **S1 / Research Question** rather than Hold, unlike the top-ranked hypertrichosis prediction, and may warrant separate evaluation despite currently having zero clinical or literature evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Taiwan Market Information

Ganirelix is **not currently licensed or marketed in Taiwan** — there are 0 authorization records on file, so no product/dosage-form/indication table can be generated.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA package-insert warnings/contraindications are flagged as a **Blocking** data gap (DG001) in this evidence pack — this must be resolved before any S1 safety pre-assessment can proceed.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Hypertrichosis) has an extremely high TxGNN score but zero supporting clinical trials, zero literature, and the evidence pack's own mechanistic review judges the biological rationale as weak. This does not meet the bar to advance past S0.

**To proceed, the following is needed:**
- TFDA package insert (warnings/contraindications) — currently blocking (DG001)
- DrugBank MOA data to formally validate the mechanistic rationale (DG002)
- Original indication / regulatory history for ganirelix (currently absent from this evidence pack)
- If the program wants to pursue the mechanistically stronger candidates instead (central precocious puberty, aromatase excess syndrome, familial male-limited precocious puberty), a dedicated literature/trial search is needed, as none currently exists for any of them
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

